Key result
Single doses of and test formulations of telmisartan met regulatory requirements for bioequivalence to the reference formulations in healthy Mexican male volunteers.
Why the study?
Are the test formulations of telmisartan 40 mg and 80 mg bioequivalent to the reference formulations in healthy male volunteers?
RCT (n=64)
Single-blind
Randomized-sequence
No
Are the test formulations of telmisartan 40 mg and 80 mg bioequivalent to the reference formulations in healthy male volunteers?
The test formulations of telmisartan 40 mg and 80 mg are bioequivalent to their respective reference formulations in healthy Mexican males.
Answers are grounded in this paper and cite their sources.
Supports generic telmisartan substitution in practice; confirms regulatory bioequivalence in healthy Mexican males.
Telmisartan is a non-peptide angiotensin II receptor antagonist. In Mexico, it is indicated for the treatment of arterial hypertension and for the prevention of morbidity and mortality of patients ≥ 55 years old with high risk of cardiovascular disease. The aim of these two studies was to compare the bioavailability and to determine the bioequivalence of two test formulations containing 40 mg and 80 mg of oral telmisartan. Two separate, singledose, single-blind, randomized, two-period, crossover studies were conducted. For each study a different set of 30 male subjects completed both studies with a 14-day washout period. In both studies, the study formulations were administered after a 10-hour overnight fast. For pharmacokinetic analysis, blood samples were drawn at baseline, 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours after administration. Plasma concentrations of telmisartan were determined using HPLC coupled with a fluorescence detector. The test and reference formulations were considered bioequivalent if the 90% CI for the geometric mean test/reference ratios were within the predetermined ranges of 80% to 125%.for AUC0-t and AUC0-∞; and 75% to 133% for Cmax. In the study with telmisartan 40 mg, the 90% CI were 81.23%; 104.94% for Cmax, 92.61%; 115.41% for AUC0-t, 91.83%; and 115.05% for AUC0-∞. In the study with telmisartan 80 mg the 90% CI were 86.84%; 121.07% for Cmax, 90.51%; 110.38% for AUC0-t, 90.58%; and 110.96% for AUC0-∞. In both studies, a single dose of the test formulation met the regulatory requirements to assume bioequivalence, based on the rate and extent of absorption.
No takes yet. Share an insight, caveat, or question.
Daniel Ponce Navarrete (2015) conducted an RCT in Healthy volunteers (n=64). Telmisartan test formulation (Raas) vs. Telmisartan reference formulation (Micardis) was evaluated on Area under the plasma concentration-time curve from baseline to the last measurable concentration (AUC0-t) for 40 mg formulation (Geometric mean ratio 103.39%, 95% CI 92.61-115.41, p=<0.01). Single doses of and test formulations of telmisartan met regulatory requirements for bioequivalence to the reference formulations in healthy Mexican male volunteers.
Synapse has enriched 10 related papers. Consider them for comparative context: